



<u>Procedure</u>	<u>Result</u>	<u>Units</u>	<u>Ref Interval</u>	<u>Accession</u>	<u>Collected</u>	<u>Received</u>	<u>Reported/</u> <u>Verified</u>
Prostate Health Index Score	20			18-247-900056	04-Sep-18 10:45:00	04-Sep-18 10:45:00	14-Sep-18 06:00:12
Free PSA	2.000	ng/mL		18-247-900056	04-Sep-18 10:45:00	04-Sep-18 10:45:00	14-Sep-18 06:00:12
Free PSA Percent	50	%		18-247-900056	04-Sep-18 10:45:00	04-Sep-18 10:45:00	14-Sep-18 06:00:12
Total PSA	4.000 H	ng/mL	[0.000-3.999]	18-247-900056	04-Sep-18 10:45:00	04-Sep-18 10:45:00	12-Sep-18 00:53:38
p2PSA	150.00	pg/mL		18-247-900056	04-Sep-18 10:45:00	04-Sep-18 10:45:00	14-Sep-18 06:00:12

04-Sep-18 10:45:00 Prostate Health Index Score:
 INTERPRETIVE INFORMATION: Prostate Health Index Score

The Prostate Health Index (P Score) is indicated for use as an aid in distinguishing prostate cancer from benign prostatic conditions, for prostate cancer detection in men aged 50 years and older with total PSA between 4 and 10 ng/mL, and with digital rectal examination findings that are not suspicious for cancer. Probability of prostate cancer on biopsy based on P Score in patients with PSA between 4 and 10 ng/mL:

P Score	Probability of Cancer	95 Percent Confidence Interval
0-26.9	9.8 percent	5.2-15.4 percent
27.0-35.9	16.8 percent	11.3-22.2 percent
36.0-54.9	33.3 percent	26.8-39.9 percent
55.0 and greater	50.1 percent	39.8-61.0 percent

The P Score may also be used to determine the probability of prostate cancer on biopsy for an individual patient. Higher P Scores are associated with higher probability of prostate cancer. Prostatic biopsy is required for diagnosis of cancer.

Testing is performed with Beckman Coulter UniCel DxI 800 Access PSA, free PSA, and p2PSA assays using Hybritech calibration. Results obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

04-Sep-18 10:45:00 Free PSA Percent:
 INTERPRETIVE INFORMATION: Free PSA Percent

Probability of prostate cancer for men with non-suspicious digital rectal exam (DRE) results and PSA between 4 and 10 ng/ml by patient age:

Percent Free PSA 50-64 Years 65 to 75 Years

* Abnormal, # = Corrected, C = Critical, f = Footnote, H = High, L = Low, t = Interpretive Text, @ = Reference Lab

0-10 percent	56 percent	55 percent
11-15 percent	24 percent	35 percent
16-20 percent	17 percent	23 percent
21-25 percent	10 percent	20 percent
Greater than 25 percent	5 percent	9 percent

Testing was performed with Beckman Coulter UniCel DxI 800 Access PSA and free PSA assays using Hybritech calibration. Results obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

04-Sep-18 10:45:00 Total PSA:
INTERPRETIVE INFORMATION: Total PSA

Total PSA is the first test performed for the Prostate Health Index Score (P Score). If the total PSA result is in the range of 4 to 10 ng/mL, then reflex testing of free PSA and p2PSA, along with calculation of the P Score and percent free PSA, will be added. Additional charges will apply.

Testing was performed with Beckman Coulter UniCel DxI 800 assays using Hybritech calibration. Results obtained with different test methods or kits cannot be used interchangeably. PSA results calibrated to the WHO standard are approximately 20 percent lower than with the Hybritech calibration. Serum PSA in conjunction with digital rectal examination (DRE) is used as an aid in the detection of prostate cancer in men aged 50 years or older. Prostate biopsy is required for the diagnosis of cancer. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

* Abnormal, # = Corrected, C = Critical, f = Footnote, H = High, L = Low, t = Interpretive Text, @ = Reference Lab